Wells Fargo’s Kiora Pharmaceuticals KPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-7
Closed -$42 7200
2024
Q1
$42 Hold
7
﹤0.01% 6874
2023
Q4
$31 Sell
7
-6
-46% -$31 ﹤0.01% 7063
2023
Q3
$64 Buy
13
+12
+1,200% +$61 ﹤0.01% 6864
2023
Q2
$8 Hold
1
﹤0.01% 7478
2023
Q1
$37 Hold
1
﹤0.01% 7190
2022
Q4
$24 Hold
1
﹤0.01% 7239
2022
Q3
$0 Buy
+1
New +$78 ﹤0.01% 7030
2022
Q2
Hold
0
7172
2022
Q1
Hold
0
7465
2021
Q4
Hold
0
7543
2021
Q3
Hold
0
7263
2021
Q2
Hold
0
7179
2021
Q1
Hold
0
7148
2020
Q4
Hold
0
6763
2020
Q3
Hold
0
6631
2020
Q2
Hold
0
6572
2020
Q1
Hold
0
6515
2019
Q4
Hold
0
6572
2019
Q3
Hold
0
6560
2019
Q2
Hold
0
6507
2019
Q1
Hold
0
6266
2018
Q4
Hold
0
6512
2018
Q3
Hold
0
6485
2018
Q2
Hold
0
6449
2018
Q1
Hold
0
6474
2017
Q4
Hold
0
6254
2017
Q3
Hold
0
6387
2017
Q2
Hold
0
6341
2017
Q1
Hold
0
6401
2016
Q4
Hold
0
6355

Other funds holding KPRX

Wells Fargo's KPRX Position: Q2 2024 in Review

Wells Fargo sold out of Kiora Pharmaceuticals (KPRX) in Q2 2024, closing a stake of 7 shares — an estimated $42 sold.

Wells Fargo first reported a position in KPRX in Q3 2022 and held it in 7 quarters. The position peaked at $64 in Q3 2023. 17 funds tracked by Wall St. Rank hold KPRX as of Q2 2024.

  • Wells Fargo reported no remaining Kiora Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 7 Kiora Pharmaceuticals shares in Q2 2024, an estimated $42.
  • Wells Fargo first reported a position in Kiora Pharmaceuticals in Q3 2022 and held it in 7 quarters.
  • Wells Fargo's Kiora Pharmaceuticals position peaked at $64 in Q3 2023.
  • 17 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.